{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:05:28Z","timestamp":1791021928394,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K19893"],"award-info":[{"award-number":["JP16K19893"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106285"],"award-info":[{"award-number":["17ck0106285"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Dendritic cells (DCs) are crucial in cancer immunity, because they activate cytotoxic T cells by presenting tumor antigens. Recently, oncolytic virus therapy has been recognized as a systemic immune stimulator. We previously developed a telomerase-specific oncolytic adenovirus (OBP-301) and a p53-armed OBP-301 (OBP-702), demonstrating that these viruses strongly activate systemic antitumor immunity. However, their effects on DCs remained unclear. In the present study, the aim was to elucidate the mechanisms of DC activation by OBP-702, focusing particularly on tumor-derived exosomes. Exosomes (Exo53, Exo301, or Exo702) were isolated from conditioned media of human or murine pancreatic cancer cell lines (Panc-1, MiaPaCa-2, and PAN02) after treatment with Ad-p53, OBP-301, or OBP-702. Exo702 derived from Panc-1 and MiaPaCa-2 cells significantly upregulated CD86, CD80, CD83 (markers of DC maturation), and IFN-\u03b3 in DCs in vitro. Similarly, Exo702 derived from PAN02 cells upregulated CD86 and IFN-\u03b3 in bone marrow-derived DCs in a bilateral PAN02 subcutaneous tumor model. This DC maturation was inhibited by GW4869, an inhibitor of exosome release, and anti-CD63, an antibody targeting the exosome marker. Intratumoral injection of OBP-702 into PAN02 subcutaneous tumors significantly increased the presence of mature DCs and CD8-positive T cells in draining lymph nodes, leading to long-lasting antitumor effects through the durable activation of systemic antitumor immunity. In conclusion, tumor-derived exosomes play a significant role in DC maturation following OBP-702 treatment and are critical for the systemic activation of antitumor immunity, leading to the abscopal effect.<\/jats:p>","DOI":"10.1007\/s00262-024-03849-5","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:04:15Z","timestamp":1730797455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dendritic cell maturation is induced by p53-armed oncolytic adenovirus via tumor-derived exosomes enhancing systemic antitumor immunity"],"prefix":"10.1007","volume":"74","author":[{"given":"Tomoko","family":"Ohtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Kumon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoma","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Urata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"3849_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-immunol-100311-102839","volume":"30","author":"RM Steinman","year":"2012","unstructured":"Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1\u201322. https:\/\/doi.org\/10.1146\/annurev-immunol-100311-102839","journal-title":"Annu Rev Immunol"},{"key":"3849_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D, Sozzani S (2023) Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 20:432\u2013447. https:\/\/doi.org\/10.1038\/s41423-023-00990-6","journal-title":"Cell Mol Immunol"},{"key":"3849_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"3849_CR4","doi-asserted-by":"publisher","unstructured":"Macedo N, Miller DM, Haq R, Kaufman HL (2020) Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 8. https:\/\/doi.org\/10.1136\/jitc-2020-001486","DOI":"10.1136\/jitc-2020-001486"},{"key":"3849_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","volume":"6","author":"J Raja","year":"2018","unstructured":"Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS (2018) Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer 6:140. https:\/\/doi.org\/10.1186\/s40425-018-0458-z","journal-title":"J Immunother Cancer"},{"key":"3849_CR6","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14:642\u2013662. https:\/\/doi.org\/10.1038\/nrd4663","journal-title":"Nat Rev Drug Discov"},{"key":"3849_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/1078-0432.ccr-1075-3","volume":"10","author":"T Kawashima","year":"2004","unstructured":"Kawashima T, Kagawa S, Kobayashi N et al (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin cancer Research: Official J Am Association Cancer Res 10:285\u2013292. https:\/\/doi.org\/10.1158\/1078-0432.ccr-1075-3","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"3849_CR8","doi-asserted-by":"publisher","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-10-2333","volume":"70","author":"S Kuroda","year":"2010","unstructured":"Kuroda S, Fujiwara T, Shirakawa Y et al (2010) Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 70:9339\u20139348. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2333","journal-title":"Cancer Res"},{"key":"3849_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ymthe.2020.01.003","volume":"28","author":"N Kanaya","year":"2020","unstructured":"Kanaya N, Kuroda S, Kakiuchi Y et al (2020) Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody. Mol Ther 28:794\u2013804. https:\/\/doi.org\/10.1016\/j.ymthe.2020.01.003","journal-title":"Mol Ther"},{"key":"3849_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","volume":"153","author":"Y Shirakawa","year":"2021","unstructured":"Shirakawa Y, Tazawa H, Tanabe S et al (2021) Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments. Eur J Cancer 153:98\u2013108. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.043","journal-title":"Eur J Cancer"},{"key":"3849_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/sj.onc.1210884","volume":"27","author":"Y Endo","year":"2008","unstructured":"Endo Y, Sakai R, Ouchi M et al (2008) Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 27:2375\u20132381. https:\/\/doi.org\/10.1038\/sj.onc.1210884","journal-title":"Oncogene"},{"key":"3849_CR12","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","volume":"48","author":"Y Yamasaki","year":"2012","unstructured":"Yamasaki Y, Tazawa H, Hashimoto Y et al (2012) A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer 48:2282\u20132291. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.020","journal-title":"Eur J Cancer"},{"key":"3849_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2020.03.016","volume":"17","author":"T Koujima","year":"2020","unstructured":"Koujima T, Tazawa H, Ieda T et al (2020) Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer. Mol Ther Oncolytics 17:107\u2013117. https:\/\/doi.org\/10.1016\/j.omto.2020.03.016","journal-title":"Mol Ther Oncolytics"},{"key":"3849_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.omto.2022.09.003","volume":"27","author":"H Araki","year":"2022","unstructured":"Araki H, Tazawa H, Kanaya N et al (2022) Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Mol Ther Oncolytics 27:3\u201313. https:\/\/doi.org\/10.1016\/j.omto.2022.09.003","journal-title":"Mol Ther Oncolytics"},{"key":"3849_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00262-022-03334-x","volume":"72","author":"Y Kajiwara","year":"2023","unstructured":"Kajiwara Y, Tazawa H, Yamada M et al (2023) Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol Immunother 72:1285\u20131300. https:\/\/doi.org\/10.1007\/s00262-022-03334-x","journal-title":"Cancer Immunol Immunother"},{"key":"3849_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02583-0","author":"M Hashimoto","year":"2024","unstructured":"Hashimoto M, Kuroda S, Kanaya N et al (2024) Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-024-02583-0","journal-title":"Br J Cancer"},{"key":"3849_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15\u201316. https:\/\/doi.org\/10.1038\/358015a0","journal-title":"Nature"},{"key":"3849_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1200\/JCO.2005.03.4116","volume":"24","author":"T Fujiwara","year":"2006","unstructured":"Fujiwara T, Tanaka N, Kanazawa S et al (2006) Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 24:1689\u20131699. https:\/\/doi.org\/10.1200\/JCO.2005.03.4116","journal-title":"J Clin Oncol"},{"key":"3849_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-42934-2_1","volume":"209","author":"H Tazawa","year":"2016","unstructured":"Tazawa H, Kagawa S, Fujiwara T (2016) p53 replacement therapy for Cancer. Recent Results Cancer Res 209:1\u201315. https:\/\/doi.org\/10.1007\/978-3-319-42934-2_1","journal-title":"Recent Results Cancer Res"},{"key":"3849_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-019-1450-6","volume":"572","author":"MD Wellenstein","year":"2019","unstructured":"Wellenstein MD, Coffelt SB, Duits DEM et al (2019) Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572:538\u2013542. https:\/\/doi.org\/10.1038\/s41586-019-1450-6","journal-title":"Nature"},{"key":"3849_CR21","doi-asserted-by":"publisher","unstructured":"Xiao Q, Werner J, Venkatachalam N, Boonekamp KE, Ebert MP, Zhan T (2022) Cross-talk between p53 and wnt signaling in Cancer. Biomolecules. https:\/\/doi.org\/10.3390\/biom12030453","DOI":"10.3390\/biom12030453"},{"key":"3849_CR22","doi-asserted-by":"publisher","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF (2017) Tumor-Residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 31: 711\u2009\u2013\u200923 e4. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.003","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"3849_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19:213\u2013228. https:\/\/doi.org\/10.1038\/nrm.2017.125","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3849_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14728222.2023.2259102","volume":"27","author":"Y Kakiuchi","year":"2023","unstructured":"Kakiuchi Y, Kuroda S, Kanaya N, Kagawa S, Tazawa H, Fujiwara T (2023) Exosomes as a drug delivery tool for cancer therapy: a new era for existing drugs and oncolytic viruses. Expert Opin Ther Targets 27:807\u2013816. https:\/\/doi.org\/10.1080\/14728222.2023.2259102","journal-title":"Expert Opin Ther Targets"},{"key":"3849_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/ijc.31080","volume":"142","author":"K Jingushi","year":"2018","unstructured":"Jingushi K, Uemura M, Ohnishi N et al (2018) Extracellular vesicles isolated from human renal cell carcinoma tissues disrupt vascular endothelial cell morphology via azurocidin. Int J Cancer 142:607\u2013617. https:\/\/doi.org\/10.1002\/ijc.31080","journal-title":"Int J Cancer"},{"key":"3849_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar MA, Baba SK, Sadida HQ et al (2024) Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther 9:27. https:\/\/doi.org\/10.1038\/s41392-024-01735-1","journal-title":"Signal Transduct Target Ther"},{"key":"3849_CR27","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1016\/j.ymthe.2021.05.015","volume":"29","author":"Y Kakiuchi","year":"2021","unstructured":"Kakiuchi Y, Kuroda S, Kanaya N et al (2021) Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. Mol Ther 29:2920\u20132930. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.015","journal-title":"Mol Ther"},{"key":"3849_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/156800907780058835","volume":"7","author":"T Fujiwara","year":"2007","unstructured":"Fujiwara T, Urata Y, Tanaka N (2007) Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Curr Cancer Drug Targets 7:191\u2013201","journal-title":"Curr Cancer Drug Targets"},{"key":"3849_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1349-7006.2007.00665.x","volume":"99","author":"Y Hashimoto","year":"2008","unstructured":"Hashimoto Y, Watanabe Y, Shirakiya Y et al (2008) Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 99:385\u2013390. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00665.x","journal-title":"Cancer Sci"},{"key":"3849_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/MMBR.00063-15","volume":"80","author":"HM van Dongen","year":"2016","unstructured":"van Dongen HM, Masoumi N, Witwer KW, Pegtel DM (2016) extracellular vesicles exploit viral entry routes for cargo delivery. Microbiol Mol Biol Rev 80:369\u2013386. https:\/\/doi.org\/10.1128\/MMBR.00063-15","journal-title":"Microbiol Mol Biol Rev"},{"key":"3849_CR31","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41564-020-0740-y","volume":"5","author":"MI Costafreda","year":"2020","unstructured":"Costafreda MI, Abbasi A, Lu H, Kaplan G (2020) Exosome mimicry by a HAVCR1-NPC1 pathway of endosomal fusion mediates hepatitis a virus infection. Nat Microbiol 5:1096\u20131106. https:\/\/doi.org\/10.1038\/s41564-020-0740-y","journal-title":"Nat Microbiol"},{"key":"3849_CR32","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1158\/1078-0432.CCR-03-0599","volume":"10","author":"T Murakami","year":"2004","unstructured":"Murakami T, Tokunaga N, Waku T, Gomi S, Kagawa S, Tanaka N, Fujiwara T (2004) Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Clin cancer Research: Official J Am Assoc Cancer Res 10:3871\u20133880. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0599","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"3849_CR33","doi-asserted-by":"publisher","first-page":"1045624","DOI":"10.3389\/fimmu.2022.1045624","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang S, Sun J, Dastgheyb RM, Li Z (2022) Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression. Front Immunol 13:1045624. https:\/\/doi.org\/10.3389\/fimmu.2022.1045624","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03849-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03849-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03849-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:49:09Z","timestamp":1738259349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03849-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3849"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03849-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuo Urata is President & CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-301 and OBP-702. Hiroshi Tazawa and Toshiyoshi Fujiwara are consultants of Oncolys BioPharma, Inc. The other authors have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}